Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Microba Life Sciences Limited ( (AU:MAP) ) just unveiled an announcement.
Microba Life Sciences Limited announced a correction to a previously released Change of Director’s Interest Notice regarding Pasquale Rombola. The original notice misstated the expiry date of certain options, which has now been corrected to expire on 13 August 2027. This update ensures accurate information for stakeholders and reflects the company’s commitment to transparency.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences is a leader in microbiome diagnostics and therapeutics, aiming to enhance human health. The company utilizes advanced technology to analyze the human gut microbiome, focusing on discovering new treatments for chronic diseases and offering microbiome testing services globally. Through collaborations with prominent organizations, Microba is exploring the connections between the microbiome, health, and disease to develop innovative health solutions.
Average Trading Volume: 345,686
Technical Sentiment Signal: Sell
Current Market Cap: A$52.98M
See more insights into MAP stock on TipRanks’ Stock Analysis page.